assembly Bill A2939

2017-2018 Legislative Session

Relates to prescription drug cost transparency

download bill text pdf

Sponsored By

Current Bill Status - In Assembly Committee


  • Introduced
  • In Committee
  • On Floor Calendar
    • Passed Senate
    • Passed Assembly
  • Delivered to Governor
  • Signed/Vetoed by Governor

do you support this legislation?

You must fill out the form below in order to support or oppose this bill. X

You must login or fill out the fields below for the senator to have an accurate account of the support or opposition to this bill.

Create an account. An account allows you to officially support or oppose key legislation, sign petitions with a single click, and follow issues, committees, and bills that matter to you. When you create an account, you agree to this platform's terms of participation.
Use this box to enter a message to your senator.

Actions

view actions (1)
Assembly Actions - Lowercase
Senate Actions - UPPERCASE
Jan 23, 2017 referred to health

Co-Sponsors

A2939 - Details

Law Section:
Public Health Law
Laws Affected:
Add ยง278-a, Pub Health L
Versions Introduced in 2015-2016 Legislative Session:
A10026

A2939 - Summary

Relates to prescription drug cost transparency.

A2939 - Bill Text download pdf

                    S T A T E   O F   N E W   Y O R K
________________________________________________________________________

                                  2939

                       2017-2018 Regular Sessions

                          I N  A S S E M B L Y

                            January 23, 2017
                               ___________

Introduced by M. of A. McDONALD -- read once and referred to the Commit-
  tee on Health

AN  ACT to amend the public health law, in relation to prescription drug
  cost transparency

  THE PEOPLE OF THE STATE OF NEW YORK, REPRESENTED IN SENATE AND  ASSEM-
BLY, DO ENACT AS FOLLOWS:

  Section  1. Legislative intent. It is the intent of the legislature to
make information available to the public about the cost and  utilization
of  pharmaceutical  drugs.  To  fulfill this goal, the legislature finds
that there should be annual reporting of drug costs and use  that  would
be  of use by policymakers, government agencies and others to understand
pharmacy cost trends.
  S 2. The public health law is amended by adding a new section 278-a to
read as follows:
  S 278-A. PRESCRIPTION DRUG COST TRANSPARENCY. 1. EACH MANUFACTURER  OF
A  BRAND AND GENERIC MEDICATION THAT IS MADE AVAILABLE IN NEW YORK STATE
SHALL FILE A REPORT ON PHARMACEUTICAL COSTS AS OUTLINED IN THIS SECTION.
  2. THE MANUFACTURER OF A PHARMACEUTICAL  DRUG  THAT  HAS  A  WHOLESALE
ACQUISITION  COST  OF ONE THOUSAND DOLLARS FOR A THIRTY DAY SUPPLY SHALL
FILE A REPORT PURSUANT TO THIS SECTION ON THE COSTS FOR EACH  QUALIFYING
DRUG. WHOLESALE ACQUISITION COST SHALL HAVE THE SAME MEANING AS FOUND IN
SUBSECTION (C) OF 42 U.S. CODE SECTION 1395W-3A.
  3.  THE  MANUFACTURER  OF  A  PHARMACEUTICAL DRUG WHICH DURING A THREE
MONTH PERIOD HAS A CUMULATIVE PRICE INCREASE OF THREE TIMES THE CONSUMER
PRICE INDEX SHALL FILE A REPORT PURSUANT TO THIS SECTION  ON  THE  COSTS
FOR EACH QUALIFYING DRUG.
  4.  THE  REPORT SHALL INCLUDE THE FOLLOWING FOR EACH DRUG DESCRIBED IN
SUBDIVISIONS TWO AND THREE OF THIS SUBDIVISION:
  (A) THE TOTAL COSTS FOR THE PRODUCTION OF THE DRUG  INCLUDING  ALL  OF
THE FOLLOWING:

 EXPLANATION--Matter in ITALICS (underscored) is new; matter in brackets
                      [ ] is old law to be omitted.
                                                           LBD07661-01-7

Comments

Open Legislation comments facilitate discussion of New York State legislation. All comments are subject to moderation. Comments deemed off-topic, commercial, campaign-related, self-promotional; or that contain profanity or hate speech; or that link to sites outside of the nysenate.gov domain are not permitted, and will not be published. Comment moderation is generally performed Monday through Friday.

By contributing or voting you agree to the Terms of Participation and verify you are over 13.